Perspective Therapeutics shares are trading higher after the company announced updated interim results from its ongoing Phase 1/2a clinical trial of VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors as part of a poster presentation at the American Association for Cancer Research Annual Meeting 2026.